Lunit Inc
KOSDAQ:328130
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Lunit Inc
Total Receivables
Lunit Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Lunit Inc
KOSDAQ:328130
|
Total Receivables
₩2.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
112%
|
CAGR 10-Years
N/A
|
|
|
I
|
Infinitt Healthcare Co Ltd
KOSDAQ:071200
|
Total Receivables
₩25.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
3%
|
|
|
U
|
UBCare Co Ltd
KOSDAQ:032620
|
Total Receivables
₩27.1B
|
CAGR 3-Years
27%
|
CAGR 5-Years
1%
|
CAGR 10-Years
10%
|
|
|
L
|
LifeSemantics Corp
KOSDAQ:347700
|
Total Receivables
₩491.7m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
|
e
|
ezCaretech Co Ltd
KOSDAQ:099750
|
Total Receivables
₩15.1B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
J
|
JLK Inc
KOSDAQ:322510
|
Total Receivables
₩1.5B
|
CAGR 3-Years
93%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
Lunit Inc
Glance View
Lunit Inc., founded in South Korea, stands as a pioneering force in the application of artificial intelligence within the realm of medical technology. As a company at the intersection of healthcare and cutting-edge AI, Lunit crafts advanced solutions that enhance the diagnostic processes in radiology and oncology. The company's name, derived from "learning unit," underscores its mission to employ deep learning as a core component in transforming medical diagnostics. At the heart of Lunit’s operations are their flagship products, Lunit INSIGHT and Lunit SCOPE, which are designed to empower physicians by providing highly accurate diagnostic readings and treatment predictions. With this technology, Lunit aims to reduce diagnostic errors and improve the efficiency of medical imaging analysis, ultimately enhancing patient treatment outcomes. Lunit generates revenue through strategic partnerships and sales of their AI software solutions to hospitals and healthcare providers globally. The company's business model involves not only licensing its AI technologies but also integrating them with existing medical imaging equipment, thus enhancing the value derived from traditional diagnostic tools. By collaborating with prominent medical device manufacturers and healthcare institutions, Lunit ensures both the scalability and adaptability of its products in diverse clinical settings. Additionally, they actively engage in research collaborations and pilot programs to further their technological advancements and expand their market presence. Through these endeavors, Lunit is steadily carving out a crucial role in the healthcare sector by offering AI-driven solutions that promise to revolutionize patient care.
See Also
What is Lunit Inc's Total Receivables?
Total Receivables
2.1B
KRW
Based on the financial report for Dec 31, 2024, Lunit Inc's Total Receivables amounts to 2.1B KRW.
What is Lunit Inc's Total Receivables growth rate?
Total Receivables CAGR 5Y
112%
Over the last year, the Total Receivables growth was 37%. The average annual Total Receivables growth rates for Lunit Inc have been 9% over the past three years , 112% over the past five years .